MBX
HEALTHCAREMBX Biosciences, Inc. Common Stock
AI Insight
What's Moving MBX Today?
No stock-specific AI insight has been generated for MBX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.63$46.90
$46.39
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-25.7%
Profit Margin—
Debt / Equity—
Trading
Volume669K
Avg Volume (10D)—
Shares Outstanding47.6M
MBX News
21 articles- How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?Yahoo Finance·Jun 15, 2026
- MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)Advfn·Jun 12, 2026
- MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismYahoo Finance·Jun 12, 2026
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchBiopharmadive·Jun 11, 2026
- MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026Yahoo Finance·Jun 1, 2026
- Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 RunMotley Fool·May 27, 2026
- MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York CityYahoo Finance·May 26, 2026
- Insider Stock Buying Reaches US$1.06m On MBX BiosciencesYahoo Finance·May 15, 2026
- MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline PushMarketbeat·May 11, 2026
- MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly DosingYahoo Finance·May 11, 2026
- MBX Biosciences (MBX) CEO logs small 607-share tax sell-to-cover tradeStock Titan·May 9, 2026
- MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate HighlightsYahoo Finance·May 7, 2026
- MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant AwardYahoo Finance·May 7, 2026
- 3 Overlooked Stocks Set to Soar in 2026Motley Fool·May 5, 2026
- MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity PortfolioYahoo Finance·Apr 23, 2026
- Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share PurchaseMotley Fool·Apr 22, 2026
- Microbix Engages with Diagnostics Industry ExpertsYahoo Finance·Apr 20, 2026
- Microbix Presenting at the 2026 Bloom Burton ConferenceYahoo Finance·Apr 16, 2026
- Microbix Exhibiting & Presenting at ESCMID Global 2026Yahoo Finance·Apr 15, 2026
- Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?Yahoo Finance·Apr 4, 2026
- MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
All 21 articles loaded
Price Data
Open$42.43
Previous Close$46.39
Day High$46.90
Day Low$41.99
52 Week High$46.90
52 Week Low$9.63
52-Week Range
$9.63$46.90
$46.39
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-2.17
Dividend Yield—
Dividend / Share—
ROE-25.7%
Profit Margin—
Debt / Equity—
Trading
Volume669K
Avg Volume (10D)—
Shares Outstanding47.6M
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—